Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer cells. We are developing a universal biomarker for enabling oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs.
- Clifford A. Reid, PhD Co-Founder and CEO
- Professor Scott Manalis Co-Founder and Consultant
- Rob Kimmerling, PhD Co-founder and Director of Research and Development
- Selim Olcum, PhD Co-Founder and Director of Engineering
- Mark Stevens, PhD Co-Founder and Director of Clinical Development